glioblastoma

The hybrid retreat showcased the latest gastric cancer, blood cancer, pediatric sarcoma, glioblastoma, breast cancer, and immune micro-environment research.

Duke Neurosurgery researchers have identified a driver of resistance to immunotherapies in deadly brain tumors, which could be targeted — allowing this type of drug to do its work. 

The Eighth Annual DCI Scientific Retreat was one for the books.

Hai Yan, MD, PhD, was awarded the International Prize for Translational Neuroscience for identifying genetic mutations linked to gliomas.

The V Foundation's Victory Ride to Cure Cancer was back as a LIVE cycling event and celebration, Aug. 28. Team DCI "virtual" and in-person riders raised more than $20K.

Renowned DCI neurosurgeon-scientist Peter Fecci, MD, PhD, is one of three SoM faculty members to be inducted this year into ASCI.

This OHE-hosted talk featured director of the Patierno/George/Freedman Lab Jennifer Freedman, PhD, and postdocs Tyler Allen, PhD, and Sean Piwarski, PhD.

Two of the 3 fellows selected to receive Duke CTSA TL1 Post-Doctoral Training Program Award this month are engaged in cancer-related research.

The finding from a genetic analysis of tumors treated with Duke’s poliovirus therapy suggests a predictive biomarker for survival.

After losing their "brain sister," three "brain brothers" carry on her message of hope in the fight against brain cancer.

The authors, including corresponding author Madan Kwatra, MD, report that osimertinib inhibits the constitutive activity of EGFRv III tyrosine kinase with high potency.